Otros idiomas Bio-Techne Corporation

Acciones

TECH

US09073M1045

Biotecnología e investigación médica

Mercado cerrado - Nasdaq Otros sitios de cotización 22:00:00 05/03/2026			Variación 5 días	Varia. 1 de enero.
55,89 ^USD	-3,39 %		-3,50 %	-4,97 %

03/03	Bio-Techne Corporation Presents at TD Cowen 46th Annual Health Care Conference, Mar-03-2026 11:10 AM
18/02	Cleo Diagnostics elige la plataforma de Bio-Techne como instrumento de inmunoensayo para su prueba sanguínea de cáncer de ovario; las acciones suben un 3%	MT

Otros idiomas

24/02	Bio-Techne to Present at Upcoming Investor Conferences
18/02	Cleo Diagnostics Selects Bio-Techne's Platform as Immunoassay Instrument for Ovarian Cancer Blood Test; Shares Jump 3%
16/02	Bio-Techne's Ella Platform Achieves Ce-Ivd Marking Expanding Access to Rapid, Cartridge-Based Immunoassays for European Clinical Laboratories
16/02	Bio-Techne Corp's Ella platform receives CE-IVD marking, available for sale in EU
16/02	Bio-Techne's Ella Platform Achieves CE-IVD Marking Expanding Access to Rapid, Cartridge‑Based Immunoassays for European Clinical Laboratories
11/02	Bio-Techne announces changes to its leadership team
11/02	Bio-Techne Corporation Announces Executive Changes, Effective March 1, 2026
11/02	Bio-Techne Announces Changes to its Leadership Team
04/02	Tranche Update on Bio-Techne Corporation's Equity Buyback Plan announced on May 6, 2025.
04/02	Bio-Techne Corporation Reports Earnings Results for the Second Quarter and Six Months Ended December 31, 2025
04/02	Biotech firm Bio-Techne beats quarterly estimates on strength in key unit
04/02	Bio-Techne Corp announces dividend of $0.08 per share for Q4 2025
04/02	Bio-Techne Declares Quarterly Dividend of $0.08 a Share, Payable Feb. 27 to Shareholders of Record on Feb. 16
04/02	Bio-Techne Fiscal Q2 Adjusted Earnings Rise, Revenue Falls
04/02	Bio-Techne Corporation Declares Dividend for the Quarter Ended December 31, 2025, Payable on February 27, 2026
04/02	Earnings Flash (TECH) Bio-Techne Corporation Reports Q2 Revenue $295.9M, vs. FactSet Est of $290.5M
04/02	Earnings Flash (TECH) Bio-Techne Corporation Posts Q2 Adjusted EPS $0.46 per Share, vs. FactSet Est of $0.43
04/02	Bio-Techne Declares Dividend
04/02	Bio-Techne Releases Second Quarter Fiscal 2026 Results
02/02	Bio-Techne Expands 3D Stem Cell and Organoid Culture Portfolio with A Fully Defined Synthetic Alternative
02/02	Bio-Techne expands 3D stem cell & organoid culture portfolio
02/02	Bio-Techne Launches Cultrex Synthetic Hydrogel to Support 3D Stem Cell, Organoid Research
02/02	Bio-Techne Expands 3D Stem Cell and Organoid Culture Portfolio with a Fully Defined Synthetic Alternative
28/01	Bio Techne : Launches Simple Plex Ultra-Sensitive Assays on Ella Platform to Enable Femtogram-Level Detection of Neurological Biomarkers
28/01	Bio-Techne Launches Simple Plex Ultra- Sensitive Assays on Ella Platform to Enable Femtogram-Level Detection of Neurological Biomarkers